GSK in Wavre produces new-generation vaccine

The vaccination campaign has already had to be adjusted several times recently due to delays in the originally planned delivery of vaccines. Pfizer/BioNTech, AstraZeneca and Moderna, among others, already have a coronavirus vaccine on the market and UK pharmaceutical giant GSK is currently working on a candidate with Germany's CureVac. It is in the final phase of human clinical trials. If all goes well, GSK could produce 100 million doses this year on its Wavre site in Walloon Brabant. One advantage of this vaccine is that it can be stored at temperatures between 2 and 8°.  It should be available in the second quarter of this year.

And there is more good news. Together with CureVac, GSK will also develop next-generation messenger RNA vaccines, which are expected to offer greater protection against variants of the virus and, as an added benefit, can be administered in a single dose. People who have not yet been vaccinated or need a booster because their initial immunity has worn off would benefit from this kind of new generation vaccine. This vaccine will be available on the market in 2022.

In the fight against coronavirus, GSK was initially expected to supply adjuvants to several firms, including Sanofi (whose vaccine is in phase 2), and Medicago of Canada. And it will continue to do so.

GSK is therefore working on all fronts to combat COVID-19 and its variants.